Recruiting
Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy
A Prospective Study on the Application of Lateral Decubitus Position in Patients with Left Breast Cancer Undergoing Adjuvant Radiotherapy
ClinicalTrials.gov IDNCT06902051
PhaseNA
Enrollment86
SponsorNanfang Hospital, Southern Medical University
Age18 Years
SexFEMALE
Conditions studied
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
About this study
A Prospective Study on the Application of Lateral Decubitus Position in Patients with Left Breast Cancer Undergoing Adjuvant Radiotherapy
Interventions
- Device: Lateral Decubitus position — Lateral Decubitus position with a special device
- Device: Lateral Decubitus device — Lateral Decubitus postion with a special device
Primary outcomes
- Radiotherapy Planning Dose-Volume Parameter -Volume of 5Gy heart dose (From study participation to the completion of the radiotherapy plan up to 2 years)
- Radiotherapy Planning Dose-Volume Parameter -Max dose of LAD (From study participation to the completion of the radiotherapy plan up to 2 years)
- Radiotherapy Planning Dose-Volume Parameter -mean heart dose (From study participation to the completion of the radiotherapy plan up to 2 years)
- Major Cardiovascular Events (From the initiation of radiotherapy to 2 years after its completion.)
- Subclinical Cardiovascular Events- Left ventricular ejection fraction (LVEF) (From the initiation of radiotherapy to 2 years after its completion.)
- Subclinical Cardiovascular Events- Left ventricular diastolic dysfunction (From the initiation of radiotherapy to 2 years after its completion.)
Eligibility information
Inclusion Criteria:
* Voluntary signing of the informed consent form
* Female patients aged 18-70 years
* Newly diagnosed left-sided breast cancer confirmed by histopathology
* No evidence of distant metastasis
* Undergoing modified radical mastectomy or breast-conserving surgery
* ECOG performance status of 0, 1, or 2
* Tolerance to radiotherapy
* Radiation field covering the entire left breast/chest wall ± regional lymphatic drainage area
Exclusion Criteria:
* Bilateral breast cancer at diagnosis
* History of breast reconstruction or implant placement on the affected side
* Prior radiotherapy to the chest or supraclavicular region
* Patients deemed unsuitable for the study based on the investigator's judgment
Study locations
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Provinse 510515 China
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Provinse 510515 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.